Salt Lake City, UT — Lipocine Inc. announced positive progress in its pivotal phase 3 clinical trial evaluating oral brexanolone (LPCN 1154) for the treatment of postpartum depression (PPD). The…
Read More
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti–microtubule binding region tau (anti–MTBR-tau) antibody currently in…
Read More
What if the next leap in psychiatric treatment doesn’t come from tweaking dopamine or serotonin, but from reengineering the immune system, harnessing neuroplasticity, or refining orexin antagonism? In 2025, the…
Read More
By mid-2025, the psychopharmacology landscape feels paradoxical: on one hand, deeply familiar challenges — slow response, heterogeneity, side effects — still dominate clinical reality. On the other, a wave of…
Read More
What if the next leap in psychiatric therapeutics comes not from entirely new receptors, but from smarter targeting—or smarter delivery? From LSD-derived anxiety relief to once-weekly schizophrenia pills, this week’s…
Read More
Key Updates Biomarker-Stratified Antidepressant ResponseA randomized trial in JAMA Psychiatry (Sept 2025) found that patients with treatment-resistant depression who carried the ANK3 biomarker had improved outcomes with liafensine, suggesting potential…
Read More
From Psychedelics to Mechanism-Driven Precision: Recent Shifts in Depression Treatment What if we could reliably predict which antidepressant will work for a patient before waiting four weeks of trial-and-error? As…
Read More
Recent changes in the legal landscape in the United States have affected access to abortion, and this restricted access has profound effects on both physical and mental health of reproductive-aged…
Read More
The FDA’s Psychopharmacologic Drugs Advisory Committee is evaluating a New Drug Application (NDA) for a combination of brexpiprazole and sertraline as a potential treatment for posttraumatic stress disorder (PTSD). If…
Read More
Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting…
Read More
A study of 1.5 million UK adults found that autoimmune diseases are linked to a nearly twofold increase in the risk for mood disorders such as depression, anxiety, and bipolar…
Read More
Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer's disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records…
Read More
An international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report 'set and setting,' the…
Read More
A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder.…
Read More
Psychological therapy has been shown to significantly alleviate depression and anxiety in stroke survivors, particularly when initiated within six months of the stroke event. In a study involving over 7,000…
Read More
Synthetic psilocybin demonstrates a significant reduction in treatment-resistant depression symptoms
A Phase 3 clinical trial of COMP360, a synthetic formulation of psilocybin, showed a significant reduction in symptoms of treatment-resistant depression. Conducted at 32 sites across the U.S. with 258…
Read More
Two new studies examining mental health risks postpartum were published online in the American Journal of Psychiatry in conjunction with Maternal Mental Health Awareness Month and the 2025 Annual Meeting…
Read More
A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels of…
Read More
Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025…
Read More
Objective Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related quality of life (HRQoL) and psychosocial functioning. Esketamine, which is…
Read More
Objective Many psychotropic drugs are highly associated with related weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established anti-obesity and glucose-lowering agents. Preliminary evidence also indicates they are fit for…
Read More
Background In VIVRE (NCT04448431), vortioxetine was associated with significantly higher rates of symptomatic and functional remission, better daily and social functioning, and greater treatment satisfaction than desvenlafaxine in patients with…
Read More
According to a brief on Medscape, supported by the NIH, The use of general anesthesia during cesarean deliveries is associated with an increased risk for postpartum depression (PPD) that necessitates…
Read More
Writing in Psychopharmacology Bulletin, Trishna Sharma, Annette C. Kestner and Abhishek Reddy described a 17-year-old female with a history of NT1 and no past psychiatric history presented to the hospital…
Read More
Writing in Psychopharmacology Bulletin, authors Chinenye Okoro, Kaye Homer, Marlene Kelbrick, Jonny Walker, Mary Sam, Justine Burge, Rosie Richards, Gabriela Paduret, and Feras Ali Mustafa examined a 53-year-old Caucasian female…
Read More
Ahmed Naguy, Nadyah Alayadhi, Saxby Pridmore, Bibi Alamiri, writing in Psychopharmacology Bulletin, made the following observations: An 11-year-old male Qatari boy was brought in to hospital by his parents for…
Read More
Salt is found in nearly every kitchen across the world; however, it is not typically thought of to be a means for suicide. Depending on the age and size of…
Read More
Crisis support lines are currently undergoing testing of artificial intelligence (AI) to assess the quality of their response. These support lines rely on well-trained counselors who are adept at handling…
Read More
According to the American Psychiatric Association's annual poll, 70% of adults in the United States report feeling anxious or extremely anxious about their own and their family's safety. This number…
Read More
According to published reports, The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Sooma Medical's portable, noninvasive neuromodulation device for treating depression, which can be administered…
Read More
Objective: To compare the efficacy and speed of achieving remission/response in treatment-resistant depression (TRD) patients treated with subanesthetic intravenous (IV) ketamine and intranasal (IN) esketamine approved by the US Food…
Read More
In a phase 2 study, pimavanserin showed promise as a treatment for major depressive disorder (MDD) when used in combination with other antidepressants. Two phase 3 studies were then conducted…
Read More
The US Food and Drug Administration (FDA) has approved the anti-amyloid beta protofibril antibody lecanemab (Leqembi, Eisai) for the treatment of early Alzheimer's disease (AD). The agency approved the treatment…
Read More
In a study published in PLOS Medicine that uses data spanning 25 years, the authors observed short sleep duration to be associated with risk of chronic disease and subsequent multimorbidity…
Read More
An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health.…
Read More
It is known that psychedelics activate serotonin 2A receptors, which eventually leads to states like increased empathy and out-of-body experiences. One of the key questions remaining n psychedelic medicine is…
Read More
Suicidal behaviors were higher during the school year (average of 6,761/month) compared to school break (average of 4,512/month). Prevalence of suicidal behaviors was highest in October for both hospitalization and…
Read More
Two drugs have emerged as the optimal medications for treating insomnia based on the "best-available evidence," but there are caveats. In a comprehensive comparative-effectiveness analysis, lemborexant and eszopiclone showed the best efficacy, acceptability, and…
Read More
Whereas symptoms of depression are known to intensify in patients who have recently experienced an incident stroke, it might also be true in such cases that the depression actually starts to worsen in…
Read More
Balovaptan, a novel drug that binds to and blocks vasopressin 1A (V1a) receptors, does not improve social communication in children and adolescents with autism spectrum disorder (ASD), new research shows. Efficacy analysis from a…
Read More
In a continuation of bad news for investigative Alzheimer's drugs, Roche has halted five early and midstage trials covering a range of therapeutic categories, including Alzheimer's drugs. The Swiss pharma…
Read More
Sage and Biogen’s depression drug quickly relieved symptoms of depression in a phase 3 trial, but the readout did little to quell concerns about the med’s durability of effect, an…
Read More
We are frequently consulted by patients with treatment resistant depression (TRD).Reference Fogelson and Leuchter1 Many of these patients have never met criteria for a manic episode so they are not diagnosed…
Read More
No pharmacological agents are approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis (DRP). Pimavanserin, an atypical antipsychotic that acts as a selective serotonin inverse agonist/antagonist…
Read More
The federal government on Thursday proposed new guidelines for prescribing opioid painkillers that remove its previous recommended ceilings on doses for chronic pain patients and instead encourage doctors to use…
Read More
Valid assessment of drug efficacy and safety requires an evidence base free of reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval packages as a gold…
Read More
A group of researchers aimed to determine the risks of premature mortality and suicide in people with common noncommunicable diseases, with and without psychiatric disorder comorbidity. In this longitudinal study…
Read More
ORIGINAL RESEARCH Doxepin for Insomnia: Executive Function before and after Treatment By Zhenghe YU, Li HAN, Pan YAN, Wenjuan LIU, Lishan REN, You XU, Lili YANG, Lisha MA, Youdan WEI,…
Read More
Orally dissolving medications containing buprenorphine are linked to severe dental problems, including total tooth loss, the US Food and Drug Administration (FDA) warns in a safety communication. The oral side effects of these medications,…
Read More
Aaron "Tim" Beck, MD, known as the father of cognitive behavioral therapy (CBT), died on Monday in Philadelphia. He was 100. Beck's pioneering career in psychoanalysis spanned more than seven…
Read More
The antidepressant fluvoxamine (Luvox) may prevent hospitalization and death in outpatients with COVID-19, new research suggests. Results from the placebo-controlled, multisite, phase 3 TOGETHER trial showed that in COVID-19 outpatients at high…
Read More
The US Food and Drug Administration (FDA) has approved a high-dose naloxone injection product for the emergency treatment of opioid overdose. ZIMHI from Adamis Pharmaceuticals is administered using a single-dose,…
Read More
Johnson & Johnson thinks a longer-acting treatment against schizophrenia will help keep patients on their prescriptions and reduce their chances of a relapse. Now, with a FDA nod under its…
Read More
Background Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis. Objective To test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of…
Read More
The objective of this research was to develop and evaluate an evidence-based suicide attempt risk checklist to aid clinicians in the identification of individuals at risk for attempting suicide in…
Read More
I cut myself for the first time today and I feel worse I'm up at 5 am writing this because I can't sleep and anxiety is keeping me up. I'm…
Read More
According to well-placed recent reports, Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA.…
Read More
There are multiple risk factors for self-harm, including a history of abuse, trauma, physical and mental illness, and bullying. Identifying these factors is a key part of prevention, ensuring that…
Read More
Three members of a US Food and Drug Administration (FDA) advisory committee are explaining why they do not support approval of the drug aducanumab (Biogen, Eisai) for the treatment of…
Read More
An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr…
Read More
Cannabis sativa has a long history of use both as a textile and as an intoxicant used for medicinal, spiritual, and recreational purposes. California voted to regulate cannabis for medical…
Read More
SUMMARY In this study, we observed that compared to women with no prior cancer, breast cancer survivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of…
Read More
From: JAMA Psychiatry. Published online October 16, 2020. doi:10.1001/jamapsychiatry.2020.3746 By Christine Moutier, MD Introduction International and US experts on suicide have expressed concerns about the potential the coronavirus disease 2019 (COVID-19)…
Read More
According to the a survey conducted by the a prominent medical association, living in the United States in 2020 is a stressful experience, even for the most even-keeled among us.…
Read More
With a vast range of medical and therapeutic benefits, CBD, or cannabidiol, is a derivative of the hemp plant. Researches have supported the claims that CBD may be a potential…
Read More
The current maintenance treatment for opiate withdrawal usually includes using a different, controlled, opiate, either methadone or buprenorphine. Alpha-2 receptor agonists, such as lofexidine, can be used to manage the…
Read More
According to Urits and Viswanath, Opioid medications are fundamental in anesthesia and analgesia and are often used to treat acute and chronic pain. They achieve their desired effects by modulating…
Read More
Chronic use of antiepileptic drugs (AEDs) can induce the development of adverse effects on bone metabolism. In epileptic patients treated with AED, the monitor- ing of biochemical markers of bone…
Read More
ABSTRACT ~ Objective: Off-label use of prazosin for posttraumatic stress disorder-related sleep disturbances (PTSD-SD) is widespread in Veterans Health Administration (VA) settings, but clinical trials have had mixed results. Trial…
Read More
ABSTRACT ~ Objectives: To sequentially study the effectiveness of lithium and divalproex monotherapy and adjunctive therapy with quetiapine or lamotrigine in the acute and continuation treatment of bipolar I or…
Read More
ABSTRACT ~ Purpose of Review: This is a comprehensive review of the association between cannabis use and psychological disorders. It reviews the latest and seminal evidence that is available and…
Read More
In a recent study, researchers described treatment-emergent sexual dysfunction (TESD) and tolerability following a switch from selective serotonin reuptake inhibitor (SSRI: citalopram, paroxetine, or sertraline) monotherapy to vortioxetine or escitalopram…
Read More
Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder…
Read More
A novel, noninvasive, over-the-counter electromagnetic neuromodulation device (ActiPatch, BioElectronics Corp.) appears to deliver long-lasting relief in chronic pain patients. Results of a long-term prospective study that included 240 patients who…
Read More
Daily intranasal insulin may be effective in slowing progression of mild cognitive impairment (MCI) or Alzheimer's disease (AD), new research suggests. The findings were presented at the Alzheimer's Association International…
Read More
According to evidence-based reviews, the answer is a qualified “Maybe.” Chronic methamphetamine use can induce pathological brain changes in the brain. Users can develop thought, mood, and behavioral disorders, including psychosis.…
Read More
Patients with prostate, bladder or kidney cancers are at greater risk of dying if they have had psychiatric care prior to the cancer treatment. In addition, patients with these cancers…
Read More
Biogen and Eisai have announced that they are discontinuing the ENGAGE and EMERGE trials, which were designed to test the efficacy and safety of aducanumab in patients with mild cognitive…
Read More
The US Food and Drug Administration (FDA) has approved brexanolone intravenous infusion (Zulresso, Sage Therapeutics), the first-ever drug indicated for the treatment of postpartum depression. The drug is administered under medical…
Read More
Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in older patients with both depression…
Read More
The Food and Drug Administration yesterday approved an intranasal form of esketamine for treatment-resistant depression in adults who have failed at least two oral antidepressants of different classes. The spray, from…
Read More
A preliminary study of five patients suffering from both depression and substance abuse disorders suggest that isn’t the case. The study was published Jan. 9 in the journal JAMA…
Read More
Furthering the role of immune system disorders in the development of mental disorders, recent research links infections that children contract during their childhood with increased risk of mental disorders during…
Read More
A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4…
Read More
A front page New York Times story read, “Every year, thousands of people addicted to opioids show up at hospital emergency rooms in withdrawal so agonizing it leaves them moaning…
Read More
Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis…
Read More
A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s…
Read More
The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response,…
Read More
By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only…
Read More
Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major…
Read More
MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at…
Read More
MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies…
Read More
Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according…
Read More
By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority…
Read More
By Marcela Almeida and Heather Burrell-Ward To the editor, We read with great interest the article by S. Thippaiah and colleagues in a recent issue of the journal. The authors reported…
Read More
Prescription Stimulant Use, Misuse, and Motivations Approximately 16 million US adults used prescription stimulants in the preceding year (annual average), 5 million misused prescription stimulants without use disorders, and 0.4…
Read More
Study Shows Continued Use of Certain Antipsychotics During Pregnancy May Increase Risk of Gestational Diabetes New York, NY. Women who take certain antipsychotic medications and continue the use of these medications through…
Read More
Background Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). This post-hoc analysis evaluates the efficacy of vortioxetine…
Read More
Autism Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol (CBD), a non-psychoactive compound found in the…
Read More
By Sereen Rose Thomson, Navin Patil, Balaji Ommurugan, and Rajesh Krishna Bhandary Abstract Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses. Sexual side…
Read More
By Johan Y. Cohen and Amélie Guilbault Abstract Due to the stringent regulatory environment for therapeutics, common side-effects of drugs in the general population are largely well-documented. This is however…
Read More
By Jacquelin Peck, MD, and Omar Viswanath, MD ABSTRACT Optimal management of chronic pain is complex and often daunting. In the pediatric and adolescent population, care-givers face additional biases in the…
Read More
A new study by the medical historian, Herwig Czech, has shed more light on the revelations that Hans Asperger, the Austrian pediatrician for whom a form of autism is named,…
Read More
The organization dedicated for decades to "Psychosomatic Medicine" will be rebranded as Consultation-Liaison Psychiatry. The name change, aimed in part at shedding the ambiguity around the word “psychosomatic” and better…
Read More
Children with comorbid autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of anxiety and mood disorders, a cross-sectional analysis has shown. “Our study supports that…
Read More
A more powerful ketamine (esketamine) nasal spray, combined with standard-of-care treatment, shows promise in quickly tamping-down depressive symptoms, according to results of a phase 2 study published April 16 in the…
Read More
For Immediate Release April 10, 2018 Los Angeles CA www.medworksmedia.com Psychopharmacology Bulletin DIGITAL ISSN: 2472-2448; PRINT ISSN: 0048-5764 From: Michael E. Thase, MD, Editor-in-Chief James La Rossa Jr., Editorial Director…
Read More
Gabapentin’s anxiolytic and sedative properties along with its overall safety profile suggest that it may be a viable adjuvant to lorazepam in the management of acute alcohol withdrawal. By Christopher…
Read More
In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis…
Read More
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar…
Read More
In a fascinating note in today's Journal of the American Medical Association (JAMA), Robert M. Post of the George Washington University School of Medicine attributes stigma as one of the main factors…
Read More
Top 5 Articles of February 2018 Updated for 2018 Dosing and Monitoring: Child and Adolescent Psychotropic Criteria For Children And Adolescents Psychotropic Drugs: Side Effects And Teratogenic Risks Recommended Clinical…
Read More
The increase in risk for alcohol use disorder (AUD) in a married individual following a diagnosis of alcoholism in the other spouse is "large and rapid," according to researchers writing…
Read More
By JoAnn E. Manson, and Shari S. Bassuk Dietary supplementation is approximately a $30 billion industry in the United States, with more than 90 000 products on the market. In recent national surveys, 52%…
Read More
According to an evidence-based review in the journal Current Psychiatry, the answer is a qualified "Maybe." Chronic methamphetamine use can induce pathological brain changes in the brain. Users can develop…
Read More
By Robin Stevenson, and Donald E. Moore Jr. Medical education is a continuum of 3 parts; undergraduate medical school education, postgraduate training, and continuing medical education (CME). CME differs from the other 2 educational components…
Read More
Eli Lilly had hoped that EXPEDITION3 would prove to the world that amyloid beta was the cause of Alzheimer’s and that solanezumab could bend the curve of cognitive decline back…
Read More
By Sheila Gupta, Tiffany Phalen, and Sanjay Gupta There is a need for additional treatment options to improve symptoms, enhance the quality of life (QOL), and reduce suffering among patients who have chronic…
Read More
NEW YORK (Thomson Reuters Foundation) - Depression and anxiety afflict Americans who are concerned with the fate of the environment, according to a study of the mental health effects of…
Read More
Hawaii, Vermont, Connecticut and Utah Round-Out Top Mississippi, Louisiana, Arkansas, Alabama, and West Virginia Bottom-Out List A year of surprises ended with one more bit of unexpected news: Massachusetts, not Hawaii,…
Read More
Taking folic acid and/or multivitamin supplements preceding and during pregnancy is associated with a lower risk of offspring developing autism spectrum disorder (ASD), an observational epidemiologic study published Jan. 3…
Read More
Demographics Remain Relatively Unchanged – Middle Aged White Men at Greatest Risk The CDC recently released the most recent data related to suicide for the year 2016. According to these…
Read More
The prevalence of autism spectrum disorder (ASD) in U.S. children and adolescents climbed to 2.41% from 2014 to 2016, Guifeng Xu, MD, and her associates, wrote in a research letter.…
Read More
Attention Bias, Threat/Anxiety Symptoms Linked A recent study indicates associations between threat bias and pediatric anxiety symptoms, and suggests that vigilance to external threats manifests more prominently in symptoms of…
Read More
Cannabidiol linked to reduction in psychotic symptoms in schizophrenia Patients with schizophrenia showed signs of improvement in positive psychotic symptoms and clinician-rated improvement after treatment with cannabidiol, a component of…
Read More
CDC researchers find > 50% of people in 10 states who died of opioid overdoses during the second half of 2016 tested positive for fentanyl. Researchers examined 5,152 people who…
Read More
A new study, published in the open-access journal Frontiers in Human Neuroscience shows that older people who routinely partake in physical exercise can reverse the signs of aging in the brain,…
Read More
Written by Dr. Bruce Kehr Psychiatrists are using genetic testing to determine which prescription medications work best for treating each patient’s particular addiction. For example, doctors can test patients who…
Read More
The FDA plans to convene an expert panel to examine the population-level effects of treating opioid addiction with medication in hopes of gaining wider acceptance of and insurance coverage for…
Read More
The Food and Drug Administration has approved an extended-release, subcutaneous injection formulation of buprenorphine for use in treating moderate to severe opioid use disorder (OUD), the manufacturer of the drug…
Read More
By Michael J. Manos, Kimberly Giuliano, and Eric Geyer The Affordable Care Act of 2010 sought to transform medical care in the United States from procedures to performance, from acute episodes of…
Read More
An investigational Alzheimer’s drug intended to potentiate acetylcholine release didn’t pass muster in a global phase 3 study, despite a successful phase 2 trial. Intepirdine on a background of stable-dose donepezil…
Read More
SAN FRANCISCO (Reuters) - Facebook Inc will expand its pattern recognition software to other countries after successful tests in the U.S. to detect users with suicidal intent, the world's largest…
Read More
Allergan plc has announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of adults with…
Read More
In 2006, psychiatrist Carlos A. Zarate Jr, MD, and colleagues at the National Institute of Mental Health (NIMH) published a seminal finding in Archives of General Psychiatry (now JAMA Psychiatry):…
Read More
The antipsychotic agent, Abilify (aripiprazole, Otsuka), is the first Food and Drug Administration approved digital pill — a medication embedded with a sensor that can tell doctors whether, and when, patients…
Read More
A long-awaited study has found that two of the main medications for treating opioid addiction are similarly effective. The study, funded by the federal government, compared Vivitrol, which comes in a…
Read More
PHARMA NEWS Takeda and Lundbeck are planning a U.S. test for a depression app that will track mood, in the hopes it will improve depression treatment. The two pharma companies have…
Read More
On individuals with major depressive disorder (MDD), particularly those who experience suicidal thinking, levels of translocator protein (TSPO), a marker of microglial inflammation, are increased, new research shows. Investigators from…
Read More
By Bruce L. Rollman, Bea Herbeck Belnap, Biol Hum, Kaleab Z. Abebe Key Points Questions Is combining an internet support group (ISG) with a care manager–guided computerized cognitive behavioral therapy (CCBT) program better at…
Read More
Longer Lives, Better Living By Bill Gates In every part of the world, people are living longer than they used to. Thanks to scientific advancements, fewer people die young from…
Read More
Viewpoint November 6, 2017 Advance Directives for Dementia: Meeting a Unique Challenge By Barak Gaster, Eric B. Larson, and J. Randall Curtis In the coming years, an increasing number of people will experience dementia. Worldwide,…
Read More
Is dorsolateral prefrontal cortex plasticity impaired in Alzheimer disease? Yes, according to researchers writing in JAMA Psychiatry. Dorsolateral prefrontal cortex plasticity is impaired in Alzheimer disease and is associated with impaired…
Read More
Perceived Addiction to Internet Porn Examined Perceived addiction to internet pornography appears to be related strongly to moral scruples around pornography use, both concurrently and over time, rather than with…
Read More
October 26, 2017 www.medworksmedia.com From: Michael E. Thase, MD, Editor-in-Chief & James M. La Rossa Jr., Editorial Director & Publisher — The Most Advanced Search Engine in Psychopharmacology — Comprehensive…
Read More
Alan F. Schatzberg, MD Madness Rising Research into Hallucinogens Gives Hope to the Hopeless and Fuels a Drug Epidemic: A Tale of Two Disparate Worlds By James M. La…
Read More
Psychopharmacology Bulletin, V47, N3: Links to In-Depth Articles ORIGINAL PRESENTATIONS Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder. By…
Read More
The prospect of millions of people unable to afford coverage led to an outcry from the health care industry as well as consumer groups. They found an uncommon ally in…
Read More
The Achilles Heel of psychiatry has always been the public's distrust of what defines a mental disorder and whether it can be treated effectively. Oftentimes, not until a trusted public…
Read More
In findings reported in a letter to the editor published online March 10 in Schizophrenia Research and reported by Medscape Medical News, the smoking cessation drug varenicline (Chantix) appears to…
Read More
Carfentanil, an opioid said to be 100 times more powerful than fentanyl, has been tied to at least 700 deaths in numerous states. Worst hit include Michigan, Florida, and Ohio,…
Read More
The number of retirement-age Americans taking at least three psychiatric drugs more than doubled between 2004 and 2013, even though almost half of them had no mental health diagnosis on…
Read More
The latest edition of Psychopharmacology Bulletin is now available at: https://medworksmedia.com/product-category/psychopharmacology-bulletin/psychopharmacology-47-no-1/. Manuscripts include: Asenapine for the Control of Physical Aggression: A Prospective Naturalist Pilot Study By Jin Shi Amon, Sarah B. Johnson,…
Read More
In a surprise to the conservative treatments by neurologists, tailored exercise treatment programs are being developed by physical therapists to specifically counter the unique movement impairments associated with Parkinson’s by…
Read More
Promising research into PTSD and the psychological effects of cancer such as anxiety and depression, have cast new light on the party drug, ecstasy (MDMA), and a hallucinogenic ingredient in "Magic…
Read More
While the debate rages whether the drug epidemic in the United States is best served by walls or treatment, millions of Americans suffer from alcoholism or addiction to legal and…
Read More
For centuries yogis have used breath control, or pranayama, to promote concentration and improve vitality. Buddha advocated breath-meditation as a way to reach enlightenment. Science is just beginning to provide…
Read More
psychopharmacology-bulletin-36-articles-uploaded-to-pubmed October 13, 2016. Los Angeles CA Contact: James La Rossa Jr., or Michael E. Thase, MD, at 310.374.1300 www.medworksmedia.com Psychopharmacology Bulletin 36 Articles Uploaded to PubMed Replica Journal…
Read More
https://medworksmedia.com/product-category/psychopharmacology-bulletin/psychopharmacology-46-2/ For Immediate Release August 18, 2016. Los Angeles CA Contact: James La Rossa Jr., or Michael E. Thase, MD, at 310.374.1300 New Issue of Psychopharmacology Bulletin ORIGINAL RESEARCH An…
Read More
My Father's generation so admired the men and women that served in World War II, that when the Korean War raised its ugly head years later, he and my uncle…
Read More
Medworks Media - 2016 MEDWORKS MEDIA June 3, 2016 Los Angeles CA www.medworksmedia.com Psychopharmacology Bulletin DIGITAL ISSN: 2472-2448; PRINT ISSN: 0048-5764 Call For Papers — 2016/2017 New Section…
Read More
I am a third-generation New Yorker. Until I moved to the minicity of Manhattan Beach, CA., in the south bay of Los Angeles, the only other place I called home…
Read More
May 17, 2016. Los Angeles, CA. My head still throbbing this morning from last night’s late arrival from Atlanta, I sought solace in the quietude of the Science Section of…
Read More
Sunday, May 15, 2016. APA Meeting, Atlanta GA. Charles B. Nemeroff, MD, PhD, the Leonard M. Miller Professor & Chairman, Department of Psychiatry and Behavioral Sciences and Director, Center on Aging…
Read More
Saturday, May 14, 2016. APA Meeting, Atlanta GA. The American Psychiatric Association (APA) convocation, which began today, highlighted initial findings in a number of key and unique mental diseases. Adopting…
Read More
Citing Stigma of Mental Illness, Weil Family Donates $185 Million for Neuroscience Center at U.C.S.F
The philanthropists, Sanford I. Weill and his wife, Joan, have made the largest donation in the University of California, San Francisco's (UCSF) history, to finance a neuroscience center to provide…
Read More
For Immediate Release April 13, 2016. Los Angeles CA www.medworksmedia.com Psychopharmacology Bulletin Volume 46, Number 1, 2016, On-Line Now Replica Journal Issue Available for Readers ORIGINAL RESEARCH A…
Read More
For anyone who has had the great pleasure of reading Siddhartha Mukherjee's 2011 Pulitzer Prize winning "The Emperor of All Maladies: A Biography of Cancer," expect something very special when…
Read More
In a recent study, researchers looked at the possibility of using nutritional intervention to slow the onset of certain Alzheimer’s symptoms. The study involved a particular nutritional drink called Souvenaid…
Read More
For Immediate Release March 7, 2016. Los Angeles CA Contact: James La Rossa Jr., 310.374.1300 2016 Issues, Set for Index Medicus, are In Press Psychopharmacology Bulletin — reactivated by the…
Read More
In the summer of 1997, I was months away from launching the first consumer magazine about mental illness. My company had acquired a state and federal trademark for the title,…
Read More
Other than the obvious onset of the mental disorder itself, postpartum depression is one of those illnesses that is hard to predict, and according to published records, may be even…
Read More
Proton Pump Inhibitor's (or P.P.I.s), widely available by prescription or over the counter brands like Prevacid, Nexium, and Prilosec, have been tied to Alzheimer's Disease and other dementias, according to…
Read More
Michael E. Thase, Charles B. Nemeroff and Philip T. Ninan round out the group.
Read More
By Catherine Lombard, Cheryce Harrison, Samantha Kozica, Sophia Zoungas, Sanjeeva Ranasinha, and Helena Teede Abstract Background Obesity is reaching epidemic proportions in both developed and developing countries. Even modest weight gain increases the risk for…
Read More
From The New York Times, Thursday, January 28. Scientists reported on Wednesday that they had taken a significant step toward understanding the cause of schizophrenia, in a landmark study that…
Read More
According to Richard A. Friedman, a professor of clinical psychiatry and the director of the psychopharmacology clinic at the Weill Cornell Medical College, writing in Sunday's New York Times, "Who among us hasn’t…
Read More
In a clear signal that medicine and politics make strange bedfellows, a crucial Senate committee on Tuesday, which unanimously approved Dr. Robert M. Califf, a cardiologist and clinical trial expert from…
Read More
For Immediate Release December 31, 2015. Los Angeles CA Contact: James La Rossa Jr., 310.374.1300 MedWorks Media Inc., established in 1994 as one of the largest publishers of journals and…
Read More
The Effect of Food on the Absorption of Oral Ziprasidone By Jeffrey J.Miceli, PhD, Paul Glue, MD, PhD, Jeffrey Alderman, PhD, and Keith Wilner, PhD
Read More
What is this new insanity drug of abuse known as gravel or flakka? Recent news reports detail a man, who thought he was being chased by dozens of cars, using…
Read More
Rexulti: New treatment for schizophrenia and major depressive disorder approved and released by FDA On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to treat adults…
Read More
The Efficacy and Tolerability of Once-daily Controlled-release Trazodone for Depressed Mood, Anxiety, Insomnia, and Suicidality in Major Depressive Disorder By David V. Sheehan, MD, MBA; Anna Rozova, MSc, MD; E.…
Read More
Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE-BASED MEDICINEORIGINAL RESEARCH: The Trials and Travails Atypical Antipsychotic Drugs and Diabetes in the…
Read More
• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE • GENERAL PSYCHIATRY Seroquel Once a Day: A Randomized, Double-Blind, Placebo-Controlled Study— This 6-week, randomized, double-blind study aimed to demonstrate efficacy of once-daily…
Read More
Newsletter No. 3, 2008 www.psychopharmbulletin.com Volume 41 • Number 3 • 2008 Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE…
Read More
Newsletter No. 2, 2008 www.psychopharmbulletin.com Volume 41 • Number 2 • 2008 Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press • ORIGINAL…
Read More
• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE ORIGINAL RESEARCH: The Trials and Travails Placebo-Controlled — PTSD Double-Blind — ADHD Pilot-Controlled — GAD Comparative Analysis — ANTIDEPRESSANT TRIALS A Placebo-Controlled Trial…
Read More
Psychiatry in the Postgenomic Era Kathy L. Kopnisky, PhD Steven E. Hyman, MD Dr. Kopnisky is assistant to the director, and Dr. Hyman is director, both at the National Institute…
Read More
Pharmacogenomics of Antidepressants: Drug Discovery, Treatment, and Ethical Considerations Julio Licinio, MD Jonas Hannestad, MD, PhD Ma-Li Wong, MD Dr. Licinio is professor of psychiatry and biobehavioral sciences and medicine/endocrinology…
Read More
THE ADVANCE NEWSLETTER OF PSYCHOPHARMACOLOGY BULLETIN Summary—Index of This Issue On-Press Newsletter No. 4, 2007 www.psychopharmbulletin.com Volume 40 • Number 3 • 2007 This newsletter is a synopsis of topical…
Read More
THE ADVANCE NEWSLETTER OF PSYCHOPHARMACOLOGY BULLETIN Summary—Index of This Issue On-Press Newsletter No. 5, 2007 www.psychopharmbulletin.com Volume 40 • Number 3 • 2007 This newsletter is a synopsis of topical…
Read More
Functional images of the brain and psychopharmacology Dr. Humberto Nicolini The various techniques of functional brain imaging have evolved surprisingly Ulti-mos in 15 years. Since the appearance of the skull…
Read More
Abstracts of the XII World Congress of Psychiatry of the World Association of Psychiatry in Yokohama, Japan Chosen by Drs. John E. Mezzich and Miguel R. Jorge Profile of…
Read More
Abstracts of XVII Peruvian Congress of Psychiatry "Federico Sal y Rosas" Bolivarian II Regional Meeting of the Latin American Psychiatric Association and I Regional Meeting of the World Psychiatric Association…
Read More
Summaries from the World Congress of Sexology held in Havana, Cuba, from 10 to 14 March Chosen by Dr. Carlos Berganza The role of hotlines in clinical sexology: the…
Read More
Publisher’s Statement New York: 9/11/01 A Personal Reckoning By James La Rossa Jr. There are two roadway approaches to New York City from which the awesome grandeur and sheer power…
Read More
